Cancer Drug Deal: IMPACT Therapeutics and Pharmanovia signed an exclusive licensing agreement worth up to €423.5m for senaparib, a PARP1/2 inhibitor, covering manufacture, development and commercialization across 66 countries including Liechtenstein, with an EMA review for first-line ovarian cancer maintenance expected in the second half of 2026. COVID-19 Update: The European Commission granted marketing authorisation for Pfizer-BioNTech’s 2026–2027 COVID-19 vaccine adapted to the XFG variant, approved for EU states plus Iceland, Liechtenstein and Norway for people aged 6 months and older. Public Health Research: A new push for a “functional cure” for chronic hepatitis B highlights that vaccines prevent infection but don’t cure those already living with the disease; researchers say immune-targeting approaches may finally change outcomes. Patient Safety & Supply Chains: Ivoclar introduced a verification program for authorised dental product distributors, warning that counterfeit and gray market items can bypass safety standards and lead to compromised treatment or patient harm. Health Policy & Access: A report spotlights how Liechtenstein’s strict abortion laws can delay or block care, pushing some people to seek services across the border. Travel & Health Costs: Coverage on travel insurance for older people notes fewer options and tighter restrictions as age cut-offs rise. Border Rules Explained: A guide explains Schengen visa requirements for visiting Spain, listing Liechtenstein among the Schengen countries.